Clinical-only: Metabolic / Weight Loss (Retatrutide + Cagrilintide)

B84· Mostly solid

Public • 06 Feb 2026

Investigational/clinical agents with strong RCT evidence in obesity-related indications (not supplements).

← Back Try alternative layout

Buy stack

Clinical-only: Metabolic / Weight Loss (Retatrutide + Cagrilintide)

metabolic weight-loss clinical-only

Retatrutide (LY-343794)

PLACEHOLDER

MODERATE

1mg

Cagrilintide

PLACEHOLDER

MODERATE

1mg

No interactions detected

Each dose includes evidence rationale · doses personalized to your weight

Stack note

Private note on this stack

Track how this stack felt, what you want to change next cycle, or anything you want to save privately in your member zone.

AI risk assessment

Context: No wearable data

PROAI risk assessment is available with Pro.

See plans

Stack pre-check

No personal data connected — connect wearables or upload bloodwork for a personalised check

Clean

Supplements

Training load

Unknown

No flags

No duplication, stimulant, interaction, or recovery concerns detected.

Pre-check is rule-based, not medical advice. Consult a healthcare professional for personalised guidance.

Interaction Analysis

Pharmacokinetic + pair-level checks

Timing optimizations

Retatrutide (LY-343794)

Take ~72h before the intended effect window

Reaches peak plasma concentration in ~72h. Half-life ~150h.

Cagrilintide

Take ~24h before the intended effect window

Reaches peak plasma concentration in ~24h. Half-life ~168h.

Interaction analysis is based on peer-reviewed pharmacology. PMID links go to PubMed. Not medical advice.

Supplements

2 items

Retatrutide (LY-343794)High

PLACEHOLDER • Other •

Human phase 2 RCT evidence for weight loss in obesity.

Buy ingredient →

1mg

Body weight reduction

High

Population: Adults with obesity (without diabetes) in a randomized controlled phase 2 trial

Study type: Randomized, double-blind, placebo-controlled phase 2 trial

Dose context: 12 mg typical (range: 1–12 mg) • Duration: 48 weeks

Retatrutide produced substantial mean body-weight reductions over 48 weeks (up to ~24% at highest dose), with larger losses at higher doses; GI adverse effects were common & dose-related.

Citation: Jastreboff et al., N Engl J Med (2023) — Triple–Hormone-Receptor Agonist Retatrutide for Obesity•DOI: 10.1056/NEJMoa2301972•https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

Phase 3 registrational program design (TRIUMPH)

Low

Population: Adults with obesity ± OSA, knee osteoarthritis, or cardiovascular disease (>5800 participants across 4 trials)

Study type: Phase 3 registrational program design/rationale publication

Dose context: — • Duration: Ongoing (trials projected through 2025–2026)

The TRIUMPH phase 3 program (4 trials, >5800 participants) evaluates once-weekly subcutaneous retatrutide vs. placebo for weight management & obesity-related complications (OSA, OA, CVD). No primary efficacy results published as of early 2026; design & rationale published in 2025.

Citation: Wadden et al., Diabetes Obes Metab (2025) — Retatrutide for obesity, OSA and knee OA: Rationale and design of TRIUMPH•https://pubmed.ncbi.nlm.nih.gov/41090431/

CagrilintideLow

PLACEHOLDER • Other •

Clinical trial evidence in obesity programs (often combination development).

Buy ingredient →

1mg

Weight loss & glycemic control — late-stage trial report (type 2 diabetes)

Low

Population: Adults with type 2 diabetes (CagriSema vs semaglutide)

Study type: Late-stage trial (news report; now superseded by peer-reviewed NEJM publication above)

Dose context: — • Duration: 68 weeks

Reuters news report (February 2026) described CagriSema outperforming semaglutide in a late-stage diabetes trial; this is now confirmed by the peer-reviewed REDEFINE 2 NEJM paper (see above).

Citation: Reuters (2026-02-02) — Novo Nordisk says CagriSema outperforms semaglutide in late-stage diabetes trial•https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-says-cagrisema-outperforms-semaglutide-late-stage-trial-type-2-2026-02-02/

Body weight reduction (phase 3 — REDEFINE 1, overweight/obesity without diabetes)

High

Population: Adults with overweight/obesity (without diabetes), n=3417 randomized

Study type: Randomized, double-blind, placebo-controlled and active-controlled phase 3a trial

Dose context: 2 mg typical (range: 0–2 mg) • Duration: 68 weeks

CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly) produced an estimated mean body-weight reduction of -20.4% vs -3.0% with placebo at week 68 (P<0.001), superior to either component alone. GI adverse events were common (majority transient & mild-to-moderate). Published in NEJM 2025.

Citation: Lincoff et al., N Engl J Med (2025) — Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1)•DOI: 10.1056/nejmc2513141•https://pubmed.ncbi.nlm.nih.gov/40544433/

Body weight & glycemic control (phase 3 — REDEFINE 2, type 2 diabetes)

High

Population: Adults with overweight/obesity and type 2 diabetes (n=1206 randomized)

Study type: Randomized, double-blind, placebo-controlled phase 3a trial

Dose context: 2 mg typical (range: 0–2 mg) • Duration: 68 weeks

CagriSema produced mean weight loss of -13.7% vs -3.4% with placebo at week 68, & 73.5% of patients achieved HbA1c ≤6.5% vs 15.9% with placebo. GI adverse events in 72.5% of CagriSema group (mostly transient/mild-moderate). Published in NEJM 2025.

Citation: Davies et al., N Engl J Med (2025) — Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2)•DOI: 10.1056/NEJMoa2502082•https://pubmed.ncbi.nlm.nih.gov/40544432/